|
| Status |
Public on Mar 05, 2022 |
| Title |
AKT/ERK-mediated activation of CDK7-MED1-AR axis drives resistance to pan BET bromodomain inhibitor ZEN-3694 in advanced prostate cancer [RNA-Seq] |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Prostate cancer cells were cultured in the presence of the drug Zenith-3694 for a period of 16-20 weeks to develop drug-resistant cells and subjected to RNA sequencing.
|
| |
|
| Overall design |
Comparison of three different prostate cancer cell lines (VCAP, LNCAP, 22RV1) upon acquiring drug resistance.
|
| |
|
| Contributor(s) |
Asangani I, Aras S, Alhusayan M |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Feb 28, 2022 |
| Last update date |
Mar 05, 2022 |
| Contact name |
Irfan Asangani |
| E-mail(s) |
asangani@upenn.edu
|
| Phone |
215-746-8780
|
| Organization name |
University of Pennsylvania
|
| Department |
Cancer Biology
|
| Lab |
Asangani Lab
|
| Street address |
421 Curie Blvd
|
| City |
Philadelphia |
| State/province |
PA |
| ZIP/Postal code |
19104 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
| Samples (12)
|
|
| This SubSeries is part of SuperSeries: |
| GSE197773 |
AKT/ERK-mediated activation of CDK7-MED1-AR axis drives resistance to pan BET bromodomain inhibitor ZEN-3694 in advanced prostate cancer |
|
| Relations |
| BioProject |
PRJNA810969 |
Less...
More...